Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Akorn Inc (NASDAQ: AKRX) acted responsibly on behalf of investors’ profitability in the planned $4.3 billion sale to Fresenius Kabi.

On April 24, 2017, Akorn Inc (NASDAQ: AKRX) and Fresenius Kabi announced that they had entered into a merger agreement. Under the terms of the merger agreement, Fresenius will offer Akorn shareholders $34.00 per share in cash for all outstanding shares.    

Based in Lake Forest, Illinois, and founded in 1971 Akorn Inc a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally.

The investigation is looking to uncover whether Akorn Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $36.00 per share.

If you purchased Akorn Inc (NASDAQ: AKRX) prior to April 24, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185